Clinical Trial Update: Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating liposome-encapsulated daunorubicin-cytarabine (CPX-351) in combination with gemtuzumab ozogamicin for relapsed or refractory acute myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• High-risk Myelodysplastic Syndrome
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)
• Gemtuzumab ozogamicin (Mylotarg) (gemtuzumab ozogamicin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING